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Abstract
Background
International comparisons of trajectories of depressive symptoms in older adults are scarce
and longitudinal associations with co-morbid conditions not fully understood.
Objective
To compare trajectories of depressive symptoms from participants living in 10 European
Countries and identify ages at which the associations of co-morbid conditions with these tra-
jectories become more relevant.
Methods
Latent growth curve models were fitted to depressive symptoms scores from participants of
the Survey of Health and Retirement in Europe (SHARE) initiative (combined n = 21,253)
and co-morbid conditions modelled as time varying covariates. To identify the ages at which
the association between co-morbid conditions and depressive symptoms was significant the
Johnson-Neyman (JN) technique was used.
Results
The shape of depressive symptoms trajectories varied between countries, and was highly
dependent on modelling decisions. The association between the average number of co-
morbidities reported over time and depressive symptoms was consistent and positive
across countries and ages.
Conclusion
International differences in ageing-related trajectories of depressive symptoms emerged.
The longitudinal association of co-morbid conditions with trajectories of depressive
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symptoms was found, but the results overall suggest that modelling decisions could greatly
influence the outcomes, and should thus be interpreted with caution.
Introduction
Depression, a mood disorder that causes a persistent feeling of sadness and loss of interest in
activities, is a major contributor to the burden of disease world wide [1,2]. In older adults, sev-
eral chronic conditions including diabetes, ischaemic heart disease, heart failure, chronic
obstructive pulmonary, Parkinson’s disease, stroke have been identified as independent risk
factors for depression [3]. However, in middle- and older aged adults, these conditions tend to
coexist. The presence of several chronic conditions has been shown to increase the risk of
depression over and above having a single one of the conditions [4] and the prevalence of mul-
tiple co-morbid conditions increases with age [5] making the association between the presence
of multiple conditions and depression in older adults particularly relevant. This further esca-
lates as the number of depressive symptoms reported by older adults grows in an accelerating
manner with increasing age [6] and individuals report a varying number of co-morbid condi-
tions over time [7]. Therefore, if the association between depressive symptoms and co-morbid
conditions is only looked at a single point in time, the dynamics of the association between
depressive symptoms and multimorbidity is overlooked. Hence, to fully understand the associ-
ation between the presence of multiple chronic conditions and depressive symptomatology in
older adults it becomes essential to evaluate longitudinal measurements of both, and apply
adequate statistical methodologies that account for their changing nature.
Rast et al [8] examined changes in depressive symptoms as individuals approach death in a
sample of deceased participants of the Health and Retirement Study (HRS). They fitted a linear
mixed model to depressive symptoms scores expressed as a function of years to death and
treated co-morbidities as time varying covariates. This modeling approach allows understand-
ing the change in depressive symptoms as individuals approach death, and obtaining separate
estimates of how the effect of co-morbid conditions on depressive symptoms varies over time.
To examine whether the change in depressive symptoms scores may be better described as a
non-linear, they modelled their trajectory with a second order polynomial.
The use of second order polynomials for modelling nonlinear trajectories is common in
research. In a second order polynomial, the zero order term (intercept) represents the level of
the outcome (conditional on covariates) at time 0, the first order term (linear slope) represents
the instantaneous rate of change at time 0 and the second order term (quadratic slope) repre-
sents a factor of the change in rate of change (acceleration or deceleration) over time. By defini-
tion, the linear slope in a second order polynomial is dependent on the placement of the
intercept and its statistical significance may also be dependent on such placement. That is, it is
possible that for some values of the intercept, the linear slope does not reach statistical signifi-
cance whereas it does reach significance levels for other values of the intercept. Even more, the
association of covariates with the linear slope may also be dependent on the placement of the
intercept. Although regions of significance of the linear slope could be identified using a pick a
point approach [9], where the intercept is placed at different values and models re-estimated for
each of these values, the JN technique [10] facilitates their estimation. This simple technique
permits the calculation of regions of significance for a simple slope of a focal predictor on an
outcome variable across a range of the second continuous independent variable. Rast et al. used
this technique to “identify conditions and times under which multimorbidity plays a role in
depression. . . and when such an association may require less attention or less treatment” [8].
Depressive symptoms and co-morbid conditions
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Although Rast and colleagues’ work provides important insights into the interplay between
changes in depressive symptoms and multimorbidities, it does so in the context of changes
before death and uses data from deceased individuals from a single study. In the current study,
we aim to examine trajectories of change in depressive symptoms whilst accounting for the
number of multimorbidities individuals report. In addition, we aim to identify ages at which
the association between multimorbidities and depressive symptoms may require more or less
attention in the context of ageing-related changes in depressive symptoms. Finally, we were
able to replicate our models using data from ten European countries that participate in the
Survey of Health, Ageing and Retirement in Europe (SHARE, www.share-project.org). Impor-
tantly, the use of such harmonized dataset maximised our ability to examine replicability of
results, across modelling decisions and different socio-cultural backgrounds.
Method
Participants
The participants were drawn from the SHARE consortia, where information on health, socio-
economic status and social and family networks of more than 85,000 individuals aged 50 and
over has been collected since 2004 across 20 European countries. The ethical approval was
granted by the Ethics Committee of the University of Mannheim for Waves 1–4. Wave 4 and
the continuation of the project were further approved by the Ethics Council of the Max Plank
Society. For each participating country, a separate approval was obtained by the respective eth-
ics committees whenever it was required (for more details on the ethical approvals see: http://
www.share-project.org/fileadmin/pdf_documentation/SHARE_ethics_approvals.pdf).
In the current study, we included data from 10 countries (Austria, Belgium, Denmark,
France, Germany, Italy, Netherlands, Spain, Sweden and Switzerland) where information
about depressive symptoms was collected in 4 occasions (waves 1, 2, 4 and 5). The total ana-
lytic sample from all ten countries combined is n = 21,253.
Depressive symptoms: The EURO-D symptom scale measures the current depression and is
constructed as a composite of 12 items: depressed mood, pessimism, suicidality, guilt, sleep,
interest, irritability, appetite, fatigue, concentration, enjoyment and tearfulness. It takes values
from 0 (not depressed) to 12 (very depressed).
Multimorbidities: At each data wave, participants were asked if the doctor ever told them
that they had: a heart attack, high blood pressure or hypertension, high cholesterol, a stroke or
cerebral vascular disease, diabetes or high blood sugar, chronic lung disease, cancer or malig-
nant tumour, stomach or duodenal ulcer, peptic ulcer, Parkinson disease, cataracts, hip frac-
ture or femoral fracture.
Table 1 shows the mean and standard deviation of depressive symptoms and chronic dis-
eases at study entry and individual sample sizes across all ten countries.
Statistical analysis
Independent linear mixed models were fitted to depressive symptoms scores from each coun-
try as a function of age at each occasion. The equation for each country is specified as follows:
Yij ¼ b0 þ b1Ageij þ b2Age
2
ij þ b3MMai þ b4MMcij þ b5BAi þ b6Ageij �MMai þ b7Ageij �MMcij
þ b8Ageij � BAi þ b9Age
2
ij �MMai þ b10Age
2
ij �MMcij þ b11Age
2
ij � BAi þ b12MMai � BAi
þ b13MMcij � BAi þ b14Ageij �MMai � BAi þ b15Ageij �MMcij � BAi þ b0i þ b1iAgeij þ εij
where Yij represents the value of EURO-D scale for individual i in occation j, b0i and b1i are
random effects for intercept and linear slope of age and εij a normal error term. To account for
Depressive symptoms and co-morbid conditions
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age differences at study entry, we adjusted the level and linear and quadratic slopes for baseline
age (BA). Following Rast’s model, we adjusted curve parameters for a time invariant variable
representing the average number of multimorbidities per person across time (MMa). We also
included a time varying variable (MMc) that represents occasion-specific deviations in multi-
morbidity from a person’s average number of multimorbidities over time and added second
and third order interaction terms with baseline age and MMa. Data from individuals who did
not report multimorbidities were excluded from the analysed sample.
We set the model intercept at three different values 5 years apart: 60, 65 and 75 years old
and also applied the JN technique. The placement of the intercept at these different ages and
the application of the JN technique allowed us to examine the significance of the linear slope at
a whole range of ages.
All analyses were conducted in Stata 13 (StataCorp, 2013) using the command xtmixed.
Models were estimated using maximum likelihood estimation, under the assumption of miss-
ing at random missing data.
Results
The level of depressive symptoms and number of co-morbid conditions at study entry varied
across countries (p< 0.05). At study entry and over the entire follow up period, Spain, Italy
and France were the countries with the highest average number of depressive symptoms, and
Denmark the country with the lowest average number of depressive symptoms. Also consis-
tently over the entire follow up period, Spain was the country with the highest average number
of chronic conditions and Switzerland the country with the lowest average number of chronic
conditions (Table 1).
Trajectories of depressive symptoms. Trajectories of depressive symptoms were inconsistent
across countries. Within countries, they also depended on the intercept placement. (See Tables
2 and 3).
When the intercept was placed at age 60, trajectories for Austria, Belgium, Denmark, Swe-
den and Switzerland exhibited accelerated change, whereas in the Netherlands and Spain the
quadratic term did not reach conventional statistical significance suggesting that depressive
symptoms changed linearly from age 60 in these two countries. In Germany and Italy, neither
slope was significant, whilst in France, change in depressive symptoms was found to consis-
tently accelerate over time.
Table 1. Depressive symptoms (EURO-D) over time by country.
Wave 1 Wave 2 Wave 3 Wave 4
Mean(st.dev) Mean(st.dev) Mean(st.dev) Mean(st.dev)
Depressive
symptoms
Chronic
conditions
N Depressive
symptoms
Chronic
Conditions
N Depressive
symptoms
Chronic
conditions
N Depressive
symptoms
Chronic
conditions
N
Austria 2.29(2.13) 0.99(1.07) 1354 2.22(2.16) 1.07(1.12) 1056 2.45(2.03) 1.24(1.26) 4146 2.26(2.02) 1.22(1.23) 3337
Belgium 2.53(2.12) 1.17(1.17) 3306 2.54(2.22) 1.14(1.15) 2810 2.83(2.20) 1.26(1.25) 4614 2.81(2.22) 1.19(1.20) 4801
Denmark 2.07(1.92) 1.07(1.22) 1381 2.06(1.84) 1.07(1.23) 2135 1.99(1.86) 1.01(1.16) 1864 2.23(1.86) 1.16(1.26) 3066
France 3.00(2.25) 1.05(1.13) 2614 2.86(2.29) 1.01(1.08) 2499 3.09(2.27) 1.17(1.20) 4934 2.98(2.24) 1.10(1.15) 3964
Germany 2.30(1.99) 1.11(1.17) 2378 2.20(1.92) 1.08(1.15) 2145 2.46(1.99) 1.32(1.26) 1411 2.81(1.94) 1.33(1.30) 4486
Italy 3.09(2.45) 1.12(1.18) 2276 2.97(2.53) 1.18(1.23) 2643 2.94(2.41) 1.17(1.18) 3118 3.34(2.52) 1.19(1.22) 3961
Netherlands 2.26(1.99) 0.96(1.12) 2388 2.12(1.94) 0.87(1.08) 2242 2.10(1.92) 0.98(1.14) 2352 2.24(1.93) 1.03(1.19) 3282
Spain 3.41(2.71) 1.23(1.24) 2090 2.98(2.63) 1.08(1.14) 1950 3.16(2.65) 1.36(1.29) 2990 3.10(2.59) 1.32(1.26) 4878
Sweden 2.20(1.90) 1.06(1.19) 2647 2.02(1.83) 1.08(1.20) 2365 2.15(1.86) 1.13(1.22) 1771 2.37(1.81) 1.19(1.27) 3641
Switzerland 2.12(1.80) 0.78(0.99) 819 1.99(1.86) 0.76(0.96) 1245 2.27(1.82) 0.88(1.06) 3124 2.09(1.77) 0.79(1.00) 2581
https://doi.org/10.1371/journal.pone.0214438.t001
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The placement of the intercept at age 65 impacted the estimated values for the trajectory
parameters and the trajectory shape in most countries. For example, in Austria, Belgium and
France, depressive symptoms accelerated at constant rate, whilst in Denmark, Sweden and
Switzerland, they also accelerated but not at constant rate. In the Netherlands and Spain,
depressive symptoms appeared to change linearly from age 65, and in Italy and Germany, a
flat trajectory was estimated.
When the intercept was placed at age 70, trajectories of depressive symptoms exhibited
accelerating change only in Belgium, France, Sweden and Switzerland. In Sweden and
Table 2. Fixed effects estimates for EURO-D.
Austria
Intercept placed at
Belgium
Intercept placed at
Denmark
Intercept placed
at
France
Intercept placed at
Germany
Intercept placed at
Fixed effects Age 60 Age 65 Age 70 Age 60 Age 65 Age 70 Age 60 Age 65 Age 70 Age 60 Age 65 Age 70 Age 60 Age 65 Age 70
Age -0.04�� -0.01 0.01 -0.03�� -0.01 0.02�� -0.04��� -0.02�� -0.01 -0.01 0.00 0.02�� -0.01 0.01 0.03���
(0.02) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01)
Baseline Age 0.02 0.02� 0.03�� 0.00 0.00 -0.01 0.01 0.01 0.01 -0.01 -0.01 -0.01 -0.02 -0.01 -0.01
(0.02) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01)
MMc 0.26��� 0.21��� 0.19��� 0.18��� 0.14��� 0.12��� 0.18��� 0.15�� 0.14�� 0.15�� 0.14�� 0.13�� 0.44��� 0.34��� 0.26���
(0.05) (0.05) (0.05) (0.04) (0.04) (0.04) (0.06) (0.06) (0.06) (0.05) (0.05) (0.05) (0.06) (0.06) (0.06
MMa 0.37��� 0.34��� 0.32��� 0.48��� 0.43��� 0.40��� 0.35��� 0.29��� 0.26��� 0.40��� 0.37��� 0.34��� 0.38��� 0.34��� 0.30���
(0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.04) (0.03) (0.03) (0.03)
Age2 0.00�� 0.00� 0.00 0.00��� 0.00��� 0.00��� 0.00� 0.00� 0.00 0.00� 0.00�� 0.00� 0.00 0.00 0.00
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Age x Baseline Age 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Age x MMc 0.00 0.00 0.01 -0.02 -0.01 0.00 -0.01 -0.01 -0.02 0.01 0.01 0.01 -0.06�� -0.05��� -0.04���
(0.02) (0.02) (0.01) (0.01) (0.01) (0.01) (0.02) (0.01) (0.01) (0.02) (0.01) (0.01) (0.02) (0.02) (0.01)
Age x MMa -0.01 0.00 0.01 -0.01 -0.01 -0.01 -0.01 -0.01 0.00 -0.02 -0.01 0.00 0.00 0.00 0.00
(0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01)
Baseline Age x MMc -0.01 -0.01 -0.01 0.00 0.00 0.00 0.00 0.01 0.01 -0.02 -0.01 -0.01 0.04� 0.03�� 0.02�
(0.02) (0.02) (0.01) (0.01) (0.01) (0.01) (0.02) (0.01) (0.01) (0.02) (0.01) (0.01) (0.02) (0.01) (0.01)
Baseline Age x MMa 0.00 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 -0.01 0.01 0.00 0.00 -0.01 -0.01 -0.01
(0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01)
Baseline Age x Age2 0.00�� 0.00�� 0.00�� 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
MMc x Age2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Mma x Age2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00� 0.00�� 0.00�� 0.00�� 0.00 0.00 0.00
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Age x Baseline Age x
MMa
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Age x Baseline Age x
MMc
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Intercept 1.79��� 1.77��� 1.90��� 2.18��� 2.09��� 2.09��� 1.80��� 1.68��� 1.64��� 2.49��� 2.43��� 2.46��� 2.06��� 1.98��� 2.01���
(0.05) (0.05) (0.06) (0.05) (0.05) (0.06) (0.05) (0.06) (0.06) (0.05) (0.06) (0.06) (0.05) (0.05) (0.05)
Note. Standard errors in parentheses.
� p< 0.10
�� p < 0.05
��� p < 0.01
https://doi.org/10.1371/journal.pone.0214438.t002
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PLOS ONE | https://doi.org/10.1371/journal.pone.0214438 April 3, 2019 5 / 11
Switzerland the linear slopes were nonsignificant, suggesting that change in depressive symp-
toms constantly accelerated with age and in Austria and Denmark, trajectories were flat. In
Germany, Italy, the Netherlands and Spain, trajectories exhibited linear change
Multimorbidities and depressive symptoms trajectories. A positive association between the
average number of multimorbidities across time (MMa) and the average number of depressive
symptoms at ages 60, 65 and 70 was consistently found in all 10 countries. This suggests that as
the number of average multimorbidities reported over time increases, the average number of
depressive symptoms at these 3 time points also increases, although estimates of these
Table 3. Fixed effects estimates for EURO-D.
Italy
Intercept placed at:
Netherlands
Intercept placed at:
Spain
Intercept placed at:
Sweden
Intercept placed at:
Switzerland
Intercept placed at:
Fixed effects Age 60 Age 65 Age 70 Age 60 Age 65 Age 70 Age 60 Age 65 Age 70 Age 60 Age 65 Age 70 Age 60 Age 65 Age 70
Age 0.00 0.01 0.02�� -0.05��� -0.04��� -0.03��� -0.08��� -0.06��� -0.04��� -0.05��� -0.03��� 0.00 -0.04��� -0.02� 0.00
(0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.02) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01)
Baseline Age -0.01 0.00 0.02�� 0.04��� 0.04��� 0.04��� 0.08��� 0.08��� 0.08��� 0.02� 0.02�� 0.01� 0.02 0.02 0.01
(0.02) (0.01) (0.01) (0.01) (0.01) (0.01) (0.02) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01)
MMc 0.35��� 0.26��� 0.20��� 0.11� 0.12�� 0.12�� 0.49��� 0.49��� 0.48��� 0.17��� 0.16��� 0.14�� 0.25��� 0.21��� 0.16��
(0.06) (0.06) (0.06) (0.05) (0.05) (0.05) (0.07) (0.06) (0.06) (0.06) (0.05) (0.05) (0.07) (0.06) (0.06)
MMa 0.57��� 0.57��� 0.57��� 0.35��� 0.33��� 0.30��� 0.52��� 0.51��� 0.50��� 0.26��� 0.24��� 0.24��� 0.39��� 0.33��� 0.29���
(0.04) (0.03) (0.04) (0.03) (0.03) (0.03) (0.04) (0.03) (0.04) (0.03) (0.03) (0.03) (0.04) (0.04) (0.04)
Age2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00��� 0.00��� 0.00��� 0.00�� 0.00�� 0.00�
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Age x Baseline Age 0.00�� 0.00�� 0.00��� 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Age x MMc -0.04�� -0.03� -0.02 0.02 0.02 0.02 0.00 -0.01 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00
(0.02) (0.02) (0.01) (0.02) (0.01) (0.01) (0.02) (0.02) (0.01) (0.02) (0.01) (0.01) (0.03) (0.02) (0.02)
Age x MMa 0.01 0.01� 0.02�� 0.00 0.00 0.00 0.01 0.01 0.02� 0.01 0.01 0.01 -0.04�� -0.02� -0.01
(0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01)
Baseline Age x
MMc
0.02 0.01 0.01 -0.02 -0.02� -0.02� 0.00 0.01 0.01 0.00 0.00 0.00 -0.01 -0.01 -0.01
(0.02) (0.01) (0.01) (0.02) (0.01) (0.01) (0.02) (0.01) (0.01) (0.02) (0.01) (0.01) (0.02) (0.02) (0.01)
Baseline Age x
MMa
-0.01 -0.02� -0.02��� 0.00 0.00 -0.01 -0.01 -0.01 -0.02�� -0.01 -0.01� -0.01�� 0.02 0.01 0.00
(0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.02) (0.01) (0.01)
Baseline Age x
Age2
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00� 0.00 0.00
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
MMc x Age2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Mma x Age2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00�� 0.00�� 0.00��
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Age x Baseline Age
x MMa
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00�� 0.00�� 0.00��
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Age x Baseline Age
x MMc
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
(0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)
Intercept 2.24��� 2.24��� 2.38��� 1.97��� 1.91��� 1.93��� 2.36��� 2.39��� 2.51��� 1.96��� 1.86��� 1.87��� 1.86��� 1.79��� 1.80���
(0.06) (0.06) (0.06) (0.05) (0.05) (0.06) (0.06) (0.06) (0.07) (0.04) (0.05) (0.05) (0.05) (0.05) (0.06)
Note. Standard errors in parentheses.
� p< 0.10
�� p < 0.05
��� p < 0.01
https://doi.org/10.1371/journal.pone.0214438.t003
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associations decreased with increasing age of intercept placement. When the intercept was
placed at ages 65 and 70, the association of MMa with the average number of depressive symp-
toms reported at these ages was age dependent only in Italy (Baseline Age X MMa). At age 70,
a similar association also emerged in Spain. These findings suggest that the effect of an increas-
ing number of multimorbidities over time on the average number of depressive symptoms at
those specific ages, decreases with older age at study entry.
The association between MMa and rate of change at ages 60, 65 and 70 was not consistent
across countries. For example, in Switzerland, our results indicate a negative significant associ-
ation between MMa and rate of change in depressive symptoms from ages 60 and 65, but at
age 70, the estimate did not reach conventional significance. Furthermore, this association was
found to change with older age at study entry although the estimate of the interaction terms
between baseline age, MMa and rate of change was very small. In other countries (Austria, Bel-
gium, Denmark and France) there was also some evidence of a negative association between
MMa and rate of change in depressive symptoms at age 60 although estimates did not reach
conventional statistical significance. Similar nonsignificant results were found in Belgium,
Denmark and France with rate of change from older ages.
In Italy, instead, MMa was found to be positively associated with rate of change at ages 65
and 70 and in Spain, with rate of change at age 70. These positive estimates suggest that rate of
change in depressive symptoms from these ages increase with an increasing number of
multimorbidities.
Fig 1. Linear slopes of EURO-D scores for the Netherlands, Sweden and Switzerland for 1–3 chronic conditions and their corresponding confidence regions
(top panel) and predicted trajectories for three different placements of the model intercept (bottom panel).
https://doi.org/10.1371/journal.pone.0214438.g001
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In all countries and independently of the age at which the intercept was set, in occasions
where the number of multimorbidities increased, the number of depressive symptoms also
increased (MMc). In most countries there was no association between occasion specific devia-
tions from the average number of multimorbidities and the linear or quadratic slopes, regard-
less of the intercept placement. Exceptions to these otherwise consistent null results were
linear rate of change at ages 60 and 65 years in Italy and the linear rate of change from all ages
in Germany.
Johnson-Neyman technique: In contrast with the previous analyses that permitted the inves-
tigation of the association of multimorbidities and rate of change at three pre specified ages,
results from the application of the JN technique allowed us to examine changes in instanta-
neous rate of change for a continuum range of different ages by a varying number of
multimorbidities.
For the sake of brevity, we present in Fig 1 a graphical representation of results from the
Netherlands, Sweden and Switzerland as these exhibited similar patters as other countries
examined. Specifically, the Netherlands exhibited a pattern of change similar to Spain, Sweden
to Austria and Switzerland to Belgium, Denmark and France. The top row of this picture
depicts linear slopes of EURO-D scores for each of the 3 countries and for 1–3 chronic condi-
tions from models where the intercept was placed at a range of different ages and confidence
regions about these slopes (dark shaded areas). Where the confidence regions include zero, the
slopes become non significantly different from zero. The ages where the linear slopes become
non significantly different from zero are marked in vertical lighter-shaded bands. For instance,
in the Netherlands, for individuals with 1 chronic condition in average, the linear slope of
depressive symptoms becomes non significant from age 70.78 years, whilst for persons with
more chronic conditions, this happens at younger ages (68.85 and 66.54 years old). The bot-
tom panel depicts predicted trajectories for models with various intercepts and number of
chronic conditions.
The bottom row of graphs depict the predicted curves for EURO-D scores for each of the 3
countries and for 1–3 chronic conditions from models where the intercept was placed at a
range of different ages.
Discussion
We evaluated the association of two dynamic processes: the number of multimorbidities indi-
viduals report with increasing age and ageing-related trajectories of depressive symptoms in
10 European countries that form part of the SHARE initiative. Using the JN technique we
demonstrated the complex nature of this association and the dependency of substantive con-
clusions on methodological decisions.
Our results indicate international differences in depressive symptoms trajectories. Impor-
tantly, our results also demonstrate the high dependency of results on the placement of the
intercept of the curve used to estimate these trajectories. For instance, whilst in Austria placing
the intercept at age 60 resulted in a trajectory of depressive symptoms that exhibited some cur-
vature and such that the linear rate of change at age 60 achieved conventional statistical signifi-
cance, this linear slope became non significant when the curve’s intercept was placed at age 65
or age 70. In contrast, in Germany, depressive symptoms did not appear to change from age 60
or 65, but they declined linearly from age 70. Consistently across countries and at the ages of
60, 65 and 70 years, a positive association was found between the average number of multimor-
bidities over time with the average level of depressive symptoms at these same ages. These
results are an illustration of the consequences of important methodological considerations that
should not be overlooked when comparing results across studies. Furthermore, these
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illustrations also suggest the need for a thorough description of statistical analyses performed
(often overlooked) when reporting results in scientific publications, so that a fair synthesis of
evidence can be performed.
Our results only partially agree with Rast ‘s, who used data from the HRS (a study harmonized
with SHARE) and a very similar statistical approach. Rast reported that depressive symptoms and
MMc appeared to increase at the end of life whilst MMa did not appear to be associated with
CES-D scores at the time of death. However, differences between their results and ours were
expected as Rast and colleagues modelled change in depressive symptoms as a function of time to
death, a metric of time different from age, the metric of time we used in our work. The choice of
an optimal metric of time to model change is a well-studied problem [11] in the cognitive ageing
literature where it has been suggested that change should be optimally modelled as a function of a
metric of time that best represent the process inducing the observed changes.
When a metric of time is defined using a land marking event such as death, a health episode
such as having a stroke, taking retirement, the moment time starts to be clocked (origin)
defines a natural intercept. However, this is not the case of age, that although it clocks time
since birth, in longitudinal studies of ageing, researchers make a somehow subjective choice
about the age they start measuring the passing of time, and consequently, about the intercept
placement. Such choice almost certainly impacts results as demonstrated in this paper, and
this impact is also dependent on the parametric curve considered. Polynomial curves are often
chosen because of ease of parameter interpretation, although when higher order polynomials
are considered, the interpretation of all parameters except the highest order term is dependent
on the placement of the intercept.
The JN technique we employed here allowed us to partly disentangle the complex associa-
tions between aging-related depressive symptoms and multimorbidities. For instance, our
results indicate that the average number of multimorbidites an individual has over time
(MMa) is consistently associated with level of depressive symptoms at ages 60, 65 and 70 years
in all countries but only changed with increasing age when the intercept was placed at age 70
in Sweden, Spain and Italy such that per extra year of older age at study entry, the effect of an
increasing number of multimorbidites became more severe. MMa was found to be associated
with instantaneous rate of change from age 70 in Spain and Italy, and with instantaneous rate
of change from age 60 in Switzerland.
Strengths and limitations
Our work has various strengths and limitations. To begin with, a strong methodological
advantage of the coordinated analytical approach considered is that results are directly compa-
rable across countries. This is the result of the harmonized design used in SHARE, but also of
the fact that as the same method was employed with covariates coded consistently across coun-
tries, estimated parameters have the same meaning across all models. This allowed for a direct
pre-publication replication of the results.
Linear mixed models assume missing data are missing at random, an assumption that may
be violated in longitudinal studies of older adults. Because an aim of our work was to illustrate
the application of the JN technique and what can be learnt from its use, whilst aiming at evalu-
ating whether patters of change in depressive symptoms and the impact of multimorbidity on
these patterns were consistent across 10 European studies, we fitted a relatively simple model
as the one employed by Rast. We encourage the further development of the models considered
here in future research.
We focused on the learning gains that result from the application of the JN technique and
its potential impact when synthesizing evidence. Although some of the previous points
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discussed may initially appear to be simple methodological considerations, we would strongly
encourage researchers not to overlook them when estimating trajectories (not only of depres-
sive symptoms as they apply to any outcome) and synthesizing evidence regarding the associa-
tions between depressive symptoms and multimorbidities, as evidence generated after fitting
alternative models may not be directly comparable, and therefore, the advancement of our
knowledge about these two processes may be hampered.
Finally, we are not able to test whether there is a causal link between the number of multi-
morbidities and depressive symptoms. While this is ultimately important as a potential target
for prevention, it is important to establish what the associations look like in a population,
whether they replicate in different populations and whether they are robust or dependent on
experimenter degrees of freedom (i.e. modelling decisions in the current study). Establishing
the true links between beteen depressive symptoms and multimorbidities is a step in the right
direction towards building a causal model of the processes in question.
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